clorgyline has been researched along with Disease Models, Animal in 26 studies
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pre-treatment with diazepam, 10 and 20mg/kg, and chlormethiazole, 50 and 100mg/kg, attenuated the development of hyperthermia." | 5.32 | Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2003) |
| "Pretreatment with risperidone (0." | 5.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| "Clorgyline treatment reduced RV afterload and pulmonary vascular remodeling in SuHx rats through reduced pulmonary vascular proliferation and oxidative stress." | 1.62 | Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension. ( Andersen, A; Andersen, S; Axelsen, JB; Bogaard, HJ; da Silva Goncalves Bos, D; de Man, FS; Gomez-Puerto, MC; Goumans, MJ; Kurakula, K; Pan, X; Peters, EL; Schalij, I; Schiepers, REJ; Sun, XQ; Szulcek, R; van der Laarse, WJ; Vonk Noordegraaf, A, 2021) |
| "Given that carriers of certain Alzheimer's disease (AD)-related PS-1 variants are predisposed to clinical depression and that depression has been historically associated with the mitochondrial enzyme, monoamine oxidase-A (MAO-A), we investigated cortical MAO-A function in the AD-related PS-1(M146V) knock-in mouse." | 1.38 | Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex. ( Baker, GB; Cao, X; Chlan-Fourney, J; Gabriel, GG; Mousseau, DD; Nazarali, AJ; Pennington, PR; Rui, L; Wei, Z, 2012) |
| " However, the neural mechanism by which extracellular 5-HT is elevated to a toxic level for the syndrome remains to be determined." | 1.35 | Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome. ( Huang, X; Krishnamoorthy, S; Ma, Z; Tao, R; Vukovich, NP; Zhang, G, 2009) |
| "Nonalcoholic steatohepatitis (NASH) is one of the most common causes of liver enzyme elevation in the West." | 1.34 | Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. ( Bader, M; Clavien, PA; Dahm, F; Georgiev, P; Jang, JH; Jochum, W; Nocito, A; Renner, EL, 2007) |
| "Pre-treatment with diazepam, 10 and 20mg/kg, and chlormethiazole, 50 and 100mg/kg, attenuated the development of hyperthermia." | 1.32 | Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2003) |
| "Pretreatment with risperidone (0." | 1.32 | Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. ( Kato, S; Nisijima, K; Shioda, K; Takano, K; Yoshino, T, 2004) |
| "Pretreatment with propranolol (10 mg/kg), a 5-HT(1A) receptor antagonist as well as a beta-blocker, and dantrolene (20 mg/kg), a peripheral muscle relaxant, did not prevent the death of the animals, even though these two drugs suppressed the increase in rectal temperature to some extent." | 1.31 | Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. ( Katoh, S; Nisijima, K; Yoshino, T; Yui, K, 2001) |
| "Parkinson disease is characterized by a major loss (approximately 80% or more) of dopaminergic nigrostriatal neurons and by an increased turnover of neurotransmitter by surviving neurons of the nigrostriatal tract." | 1.28 | Dopamine turnover and glutathione oxidation: implications for Parkinson disease. ( Cohen, G; Spina, MB, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.69) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Yeon, SK | 1 |
| Choi, JW | 1 |
| Park, JH | 1 |
| Lee, YR | 1 |
| Kim, HJ | 1 |
| Shin, SJ | 1 |
| Jang, BK | 1 |
| Kim, S | 1 |
| Bahn, YS | 1 |
| Han, G | 1 |
| Lee, YS | 1 |
| Pae, AN | 1 |
| Park, KD | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Sang, Z | 1 |
| Wang, K | 1 |
| Bai, P | 1 |
| Wu, A | 1 |
| Shi, J | 1 |
| Liu, W | 1 |
| Zhu, G | 1 |
| Wang, Y | 1 |
| Lan, Y | 1 |
| Chen, Z | 1 |
| Zhao, Y | 1 |
| Qiao, Z | 1 |
| Wang, C | 1 |
| Tan, Z | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Sun, XQ | 1 |
| Peters, EL | 1 |
| Schalij, I | 1 |
| Axelsen, JB | 1 |
| Andersen, S | 1 |
| Kurakula, K | 1 |
| Gomez-Puerto, MC | 1 |
| Szulcek, R | 1 |
| Pan, X | 1 |
| da Silva Goncalves Bos, D | 1 |
| Schiepers, REJ | 1 |
| Andersen, A | 1 |
| Goumans, MJ | 1 |
| Vonk Noordegraaf, A | 1 |
| van der Laarse, WJ | 2 |
| de Man, FS | 1 |
| Bogaard, HJ | 1 |
| van Eif, VW | 1 |
| Bogaards, SJ | 1 |
| Matsumoto, T | 1 |
| Watanabe, S | 1 |
| Taguchi, K | 1 |
| Kobayashi, T | 1 |
| Garcia-Miralles, M | 1 |
| Ooi, J | 1 |
| Ferrari Bardile, C | 1 |
| Tan, LJ | 1 |
| George, M | 1 |
| Drum, CL | 1 |
| Lin, RY | 1 |
| Hayden, MR | 1 |
| Pouladi, MA | 1 |
| Thomas, DM | 1 |
| Francescutti-Verbeem, DM | 1 |
| Kuhn, DM | 1 |
| Zhang, G | 1 |
| Krishnamoorthy, S | 1 |
| Ma, Z | 1 |
| Vukovich, NP | 1 |
| Huang, X | 1 |
| Tao, R | 1 |
| Glynn, D | 1 |
| Gibson, HE | 1 |
| Harte, MK | 1 |
| Reim, K | 1 |
| Jones, S | 1 |
| Reynolds, GP | 1 |
| Morton, AJ | 1 |
| Wei, Z | 1 |
| Gabriel, GG | 1 |
| Rui, L | 1 |
| Cao, X | 1 |
| Pennington, PR | 1 |
| Chlan-Fourney, J | 1 |
| Nazarali, AJ | 1 |
| Baker, GB | 1 |
| Mousseau, DD | 1 |
| Villarinho, JG | 1 |
| Oliveira, SM | 1 |
| Silva, CR | 1 |
| Cabreira, TN | 1 |
| Ferreira, J | 1 |
| Shioda, K | 3 |
| Nisijima, K | 5 |
| Kasai, M | 1 |
| Yoshino, T | 5 |
| Kato, S | 3 |
| Márquez, C | 1 |
| Poirier, GL | 1 |
| Cordero, MI | 1 |
| Larsen, MH | 1 |
| Groner, A | 1 |
| Marquis, J | 1 |
| Magistretti, PJ | 1 |
| Trono, D | 1 |
| Sandi, C | 1 |
| Takano, K | 2 |
| Takahata, K | 1 |
| Shimazu, S | 1 |
| Yoneda, F | 1 |
| Ogawa, M | 1 |
| Iida, Y | 1 |
| Saji, H | 1 |
| Nocito, A | 1 |
| Dahm, F | 1 |
| Jochum, W | 1 |
| Jang, JH | 1 |
| Georgiev, P | 1 |
| Bader, M | 1 |
| Renner, EL | 1 |
| Clavien, PA | 1 |
| Real, C | 1 |
| Popa, D | 1 |
| Seif, I | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Adrien, J | 1 |
| Escourrou, P | 1 |
| Crawley, JN | 1 |
| Adeyemo, OM | 1 |
| Youdim, MB | 1 |
| Markey, SP | 1 |
| Markey, CJ | 1 |
| Pollard, HB | 1 |
| Barthalmus, GT | 1 |
| Hardin, LK | 1 |
| Thompson, D | 1 |
| Ishiguro, T | 1 |
| Yui, K | 1 |
| Katoh, S | 1 |
| Spina, MB | 1 |
| Cohen, G | 1 |
26 other studies available for clorgyline and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; | 2018 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disease Models, | 2020 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Topics: Animals; Clorgyline; Disease Models, Animal; Disease Progression; Heart Ventricles; Humans; Hypertro | 2021 |
Intrinsic cardiac adrenergic (ICA) cell density and MAO-A activity in failing rat hearts.
Topics: Animals; Cell Count; Clorgyline; Disease Models, Animal; Heart Failure; Male; Monoamine Oxidase; Mon | 2014 |
Mechanisms underlying increased serotonin-induced contraction in carotid arteries from chronic type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Carotid Arteries; Clorgyline; Diabetes Mellitus, Type 2; Disease Models, Animal; In Vitro T | 2014 |
Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Topics: Animals; Brain; Clorgyline; Disease Models, Animal; Exploratory Behavior; Hindlimb Suspension; Human | 2016 |
Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity.
Topics: Animals; Clorgyline; Cytosol; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Plasma Mem | 2009 |
Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Body Temperature; Clorgyline; Cyproheptadine; D | 2009 |
Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Antidepressive Agents; Clorgyline; Disease Models, A | 2010 |
Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Cells, Cultured; Cerebral Cortex; Chromatography, | 2012 |
Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice.
Topics: Animals; Clorgyline; Disease Models, Animal; Female; Mice; Monoamine Oxidase; Monoamine Oxidase Inhi | 2012 |
Risperidone attenuates the increase of extracellular nitric oxide and glutamate levels in serotonin syndrome animal models.
Topics: 5-Hydroxytryptophan; Animals; Brain; Clorgyline; Disease Models, Animal; Fluoxetine; Glutamic Acid; | 2012 |
Peripuberty stress leads to abnormal aggression, altered amygdala and orbitofrontal reactivity and increased prefrontal MAOA gene expression.
Topics: Aggression; Amygdala; Analysis of Variance; Animals; Clorgyline; Conditioning, Psychological; Diseas | 2013 |
Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Brain; Chlormethiazole; Clorgyline; Diazepam; Diseas | 2003 |
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cell Death; Clorgyline; Disease | 2003 |
Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Body Temperature; Clorgyline; Disease Models, Animal; Dizocilpine Male | 2004 |
Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
Topics: Adult; Aged; Alanine Transaminase; Animals; Aspartate Aminotransferases; Choline Deficiency; Clorgyl | 2007 |
Sleep apneas are increased in mice lacking monoamine oxidase A.
Topics: Animals; Brain; Clorgyline; Disease Models, Animal; Mice; Mice, Knockout; Monoamine Oxidase; Neurons | 2007 |
Preliminary report of a new rodent separation model of depression.
Topics: Animals; Brain; Clorgyline; Cricetinae; Depressive Disorder; Disease Models, Animal; Female; Humans; | 1984 |
L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.
Topics: Animals; Brain; Clorgyline; Disease Models, Animal; Dopamine; Goldfish; Monoamine Oxidase; Motor Act | 1993 |
MAO-A and -B inhibitors selectively alter Xenopus mucus-induced behaviors of snakes.
Topics: Analysis of Variance; Animals; Behavior, Animal; Clorgyline; Disease Models, Animal; Movement Disord | 1993 |
Risperidone counteracts lethality in an animal model of the serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Body Temperature; Clorgyline; Disease Models, A | 2000 |
Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.
Topics: 5-Hydroxytryptophan; Animals; Anterior Hypothalamic Nucleus; Antidepressive Agents; Body Temperature | 2001 |
Dopamine turnover and glutathione oxidation: implications for Parkinson disease.
Topics: Animals; Cerebral Cortex; Clorgyline; Corpus Striatum; Disease Models, Animal; Dopamine; Glutathione | 1989 |